Marketing-authorisation holder
Hetero Drugs Ltd
3 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
3 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| LAMIVUDINE, NEVIRAPINE, AND STAVUDINE150mg; 200mg; 30mg · Tablet | Lamivudine, Nevirapine, Stavudine | United States | tentative | 2010 |
| LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE FDC TABS300mg/300mg · Tablet | Lamivudine, Tenofovir disoproxil | United States | tentative | 2009 |
| LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG150mg; 300mg; 200mg · Tablet | Lamivudine, Zidovudine, Nevirapine | United States | tentative | 2009 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 0 | 3 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.